Neuropathic pain feature in cancer-induced bone pain: does it matter? a prospective observational study
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Cancer-induced bone pain (CIBP) is considered to have both nociceptive and neuropathic components. However, the prevalence, risk factors, and impact of the neuropathic components are yet poorly understood. Methods: We estimate the prevalence of neuropathic pain (NP) features in patients with CIBP at a tertiary care pain clinic setting using the Douleur Neuropathique 4 questionnaire and evaluate their associated factors and their impact after 4 weeks of treatment using the Brief Pain Inventory questionnaire and the Edmonton Symptom Assessment System. Results: A total of 133 patients were recruited. The estimated prevalence of NP was 30.8% (95% confidence interval: 23.6%–39.1%). Initially, the patients with NP had significantly higher average pain scores (6.00 vs. 5.05, P = 0.006), higher total interference scores (5.84 vs. 4.89, P = 0.033), and symptom distress scores (35.88 vs. 26.52, P = 0.002). After 4 weeks of treatment, patients in both groups reported significantly decreased pain intensity and improved quality of life. However, the patients with NP still reported significantly higher average pain (4.61 vs. 3.58, P = 0.048), trending toward higher total interference scores (3.52 vs. 2.99, P = 0.426), and symptom distress scores (23.30 vs. 20.77, P = 0.524). From multivariate analysis, the independent risk factors for NP were younger age, pain in the extremities, and higher average pain scores. Conclusions: NP are common in patients with CIBP. These conditions negatively affect pain intensity and the patient’s quality of life before and after treatment.
Abstract
Background: Cancer-induced bone pain (CIBP) is considered to have both nociceptive and neuropathic components. However, the prevalence, risk factors, and impact of the neuropathic components are yet poorly understood. Methods: We estimate the prevalence of neuropathic pain (NP) features in patients with CIBP at a tertiary care pain clinic setting using the Douleur Neuropathique 4 questionnaire and evaluate their associated factors and their impact after 4 weeks of treatment using the Brief Pain Inventory questionnaire and the Edmonton Symptom Assessment System. Results: A total of 133 patients were recruited. The estimated prevalence of NP was 30.8% (95% confidence interval: 23.6%–39.1%). Initially, the patients with NP had significantly higher average pain scores (6.00 vs. 5.05, P = 0.006), higher total interference scores (5.84 vs. 4.89, P = 0.033), and symptom distress scores (35.88 vs. 26.52, P = 0.002). After 4 weeks of treatment, patients in both groups reported significantly decreased pain intensity and improved quality of life. However, the patients with NP still reported significantly higher average pain (4.61 vs. 3.58, P = 0.048), trending toward higher total interference scores (3.52 vs. 2.99, P = 0.426), and symptom distress scores (23.30 vs. 20.77, P = 0.524). From multivariate analysis, the independent risk factors for NP were younger age, pain in the extremities, and higher average pain scores. Conclusions: NP are common in patients with CIBP. These conditions negatively affect pain intensity and the patient’s quality of life before and after treatment.
참고문헌 (42)
- Coleman RE, "Clinical features of metastatic bone disease and risk of skeletal morbidity", Clin Cancer Res, 12(20 Pt 2), pp.6243s~6249s (2006)
- Coleman RE, "Skeletal complications of malignancy", Cancer, 80(8 Suppl), pp.1588~1594 (1997)
- Hird A, "Dexamethasone for the prophylaxis of radiation-induced pain flare after palliative radiotherapy for symptomatic bone metastases : a phase II study", Clin Oncol (R Coll Radiol), 21, pp.329~335 (2009)
- Aielli F, "Bone metastasis pain, from the bench to the bedside", Int J Mol Sci, 20, pp.280~ (2019)
- Peters CM, "Tumor-induced injury of primary afferent sensory nerve fibers in bone cancer pain", Exp Neurol, 193, pp.85~100 (2005)
- Mantyh PW, "Cancer pain and its impact on diagnosis, survival and quality of life", Nat Rev Neurosci, 7, pp.797~809 (2006)
- Obata K, "Contribution of injured and uninjured dorsal root ganglion neurons to pain behavior and the changes in gene expression following chronic constriction injury of the sciatic nerve in rats", Pain, 101, pp.65~77 (2003)
- Habberstad R, "Which factors can aid clinicians to identify a risk of pain during the following month in patients with bone metastases? A longitudinal analyses", Support Care Cancer, 27, pp.1335~1343 (2019)
- Kerba M, "Neuropathic pain features in patients with bone metastases referred for palliative radiotherapy", J Clin Oncol, 28, pp.4892~4897 (2010)
- Lechner B, "The incidence of neuropathic pain in bone metastases patients referred for palliative radiotherapy", Radiother Oncol, 118, pp.557~561 (2016)
- Nakamura N, "Neuropathic pain features in patients with bone metastases", Clin Oncol (R Coll Radiol), 28, pp.204~208 (2016)
- Bouhassira D, "Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire(DN4)", Pain, 114, pp.29~36 (2005)
- Chaudakshetrin P, "Validation of the Thai Version of Brief Pain Inventory(BPI-T)in cancer patients", J Med Assoc Thai, 92, pp.34~40 (2009)
- Chinda M, "Reliability and validity of a Thai version of the edmonton symptom assessment scale(ESASThai)", J Pain Symptom Manage, 42, pp.954~960 (2011)
- Chaudakshetrin P, "Cross-cultural adaptation to the Thai language of the neuropathic pain diagnostic questionnaire(DN4)", J Med Assoc Thai, 90, pp.1860~1865 (2007)
- WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents, "World Health Organization", World Health Organization, 21~49 (2018)
- Falk S, "Pain and nociception : mechanisms of cancer-induced bone pain", J Clin Oncol, 32, pp.1647~1654 (2014)
- Jimenez-Andrade JM, "Bone cancer pain", Ann N Y Acad Sci, 1198, pp.173~181 (2010)
- Mantyh PW, "Bone cancer pain : from mechanism to therapy", Curr Opin Support Palliat Care, 8, pp.83~90 (2014)
- Zhu XC, "Advances in cancer pain from bone metastasis", Drug Des Devel Ther, 9, pp.4239~4245 (2015)
- Yang G, "Ethnic differences in orofacial somatosensory profiles-quantitative sensory testing in Chinese and Danes", J Oral Rehabil, 40, pp.844~853 (2013)
- Zajacova A, "Beyond Black vs White : racial", ethnic disparities in chronic pain including Hispanic, Asian, Native American, and multiracial US adults, 2022, pp.163, 1688~1699
- Nekolaichuk CL, "A validation study of a pain classification system for advanced cancer patients using content experts : the Edmonton Classification System for Cancer Pain", Palliat Med, 19, pp.466~476 (2005)
- Mulvey MR, "The role of screening tools in diagnosing neuropathic pain", Pain Manag, 4, pp.233~243 (2014)
- Mulvey MR, "Neuropathic pain in cancer : systematic review, performance of screening tools and analysis of symptom profiles", Br J Anaesth, 119, pp.765~774 (2017)
- Bouhassira D, "Neuropathic pain : definition, assessment and epidemiology", Rev Neurol(Paris), 175, pp.16~25 (2019)
- Forbes HJ, "A systematic review and metaanalysis of risk factors for postherpetic neuralgia", Pain, 157, pp.30~54 (2016)
- Hébert HL, "Risk factors for neuropathic pain in diabetes mellitus", Pain, 158, pp.560~568 (2017)
- Chartier SR, "The changing sensory and sympathetic innervation of the young, adult and aging mouse femur", Neuroscience, 387, pp.178~190 (2018)
- Steverink JG, "Sensory innervation of human bone : an immunohistochemical study to further understand bone pain", J Pain, 22, pp.1385~1395 (2021)
- González-Roldán AM, "Age-related changes in pain perception are associated with altered functional connectivity during resting state", Front Aging Neurosci, 12, pp.116~ (2020)
- Lautenbacher S, "Age changes in pain perception : a systematicreview and meta-analysis of age effects on pain and tolerance thresholds", Neurosci Biobehav Rev, 75, pp.104~113 (2017)
- Richebé P, "Persistent postsurgical pain : pathophysiology and preventative pharmacologic considerations", Anesthesiology, 129, pp.590~607 (2018)
- Parineeta Thapa, "Chronic postsurgical pain: current evidence for prevention and management", The Korean Journal of Pain, 31(3), pp.155~173 (2018), 대한통증학회
- Oostinga D, "An understanding of bone pain : a narrative review", Bone, 134, pp.115272~ (2020)
- Finnerup NB, "Neuropathic pain : an updated grading system for research and clinical practice", Pain, 157, pp.1599~1606 (2016)
- Scholz J, "The IASP classification of chronic pain for ICD-11:chronic neuropathic pain", Pain, 160, pp.53~59 (2019)
- Shkodra M, "Neuropathic pain : clinical classification and assessment in patients with pain due to cancer", Pain, 162, pp.866~874 (2021)
- Brunelli C, "Classification of neuropathic pain in cancer patients: a Delphi expert survey report and EAPC", IASP proposal of an algorithm for diagnostic criteria, 2014, pp.155, 2707~2713
- Bennett MI, "Effectiveness of antiepileptic or antidepressant drugs when added to opioids for cancer pain : systematic review", Palliat Med, 25, pp.553~559 (2011)
- Nishihara M, "Combinations of low-dose antidepressants and low-dose pregabalin as useful adjuvants to opioids for intractable, painful bone metastases", Pain Physician, 16, pp.E547~E552 (2013)
- Tuchman M, "Central sensitization and Ca(V)α₂δ ligands in chronic pain syndromes : pathologic processes and pharmacologic effect", J Pain, 11, pp.1241~1249 (2010)